下丘脑性闭经 中国就医指南

Hypothalamic amenorrhea (HA) is a reversible form of secondary amenorrhea characterized by the absence of menstruation for at least three consecutive cycles due to suppression of the hypothalamic-pituitary-ovarian (HPO) axis—specifically, reduced gonadotropin-releasing hormone (GnRH) pulsatility—without structural or endocrine pathology. It is not caused by pregnancy, menopause, hyperprolactinemia, thyroid dysfunction, or polycystic ovary syndrome (PCOS), and diagnostic criteria require normal prolactin, TSH, FSH, LH, estradiol, and pelvic ultrasound findings. Pathophysiologically, HA arises from chronic energy deficit—whether from excessive exercise, restrictive eating, psychological stress, or a combination—which activates corticotropin-releasing hormone (CRH) and inhibits kisspeptin neurons in the hypothalamus. This disrupts GnRH pulse frequency and amplitude, leading to low LH/FSH secretion, anovulation, and hypoestrogenism. Epidemiologically, HA affects an estimated 5–15% of women with secondary amenorrhea in reproductive-age clinical populations, with higher prevalence among elite athletes (up to 65% in some endurance disciplines), individuals with eating disorders (e.g., anorexia nervosa), and high-achieving students or professionals under sustained psychosocial pressure. Key risk factors include low body weight or rapid weight loss (<10% of ideal body weight), high-intensity physical training (>12 hrs/week without adequate caloric compensation), chronic perceived stress (elevated cortisol), perfectionistic personality traits, and history of dieting or disordered eating patterns. Importantly, HA is not merely a menstrual symptom—it reflects systemic neuroendocrine dysregulation with significant quality-of-life implications: patients frequently report fatigue, insomnia, decreased libido, brain fog, anxiety/depression, and impaired concentration. Long-term consequences include bone mineral density loss (increasing osteoporosis and fracture risk), cardiovascular metabolic alterations (e.g., endothelial dysfunction, unfavorable lipid shifts), and potential fertility delays. Unlike organic causes of amenorrhea, HA is fully reversible with timely behavioral intervention—yet misdiagnosis as 'functional' or 'psychogenic' often delays appropriate multidisciplinary care involving reproductive endocrinology, nutrition, psychology, and exercise physiology. Early recognition and patient-centered, non-stigmatizing management are critical to restoring hormonal balance, protecting long-term health, and supporting reproductive autonomy.

# 下丘脑性闭经治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：体重过低、应激性、运动性或功能性下丘脑抑制者（FSH/LH低下、雌激素<40 pg/mL，MRI排除器质病变）

• •生活方式干预（营养+心理+减压）：3–6个月，含营养师/心理咨询随访，0–800元（含初筛激素6项、骨密度检测）
• •雌孕激素序贯治疗（如戊酸雌二醇+地屈孕酮）：周期性用药，1200–2800元/年（含每月性激素六项+肝肾功能监测）
• •促性腺激素释放激素脉冲泵（GnRH-pump）治疗：适用于特发性低促性腺激素性闭经，3.2–4.5万元/疗程（3–6个月）（含泵设备租赁、血LH峰监测、动态激素谱检测）

二、手术/介入方案

本病无根治性手术指征；仅极少数合并垂体柄受压或Rathke囊肿压迫者，需神经外科会诊评估经蝶窦微创减压术——非生殖医学科常规治疗路径，不纳入标准方案

三、特殊复杂情况处理

• •耐药型/长期闭经（>5年）伴骨质疏松：加用双膦酸盐+钙维生素D强化管理，年均额外支出2600–4200元
• •合并高泌乳素血症或垂体微腺瘤：转内分泌科联合溴隐亭/卡麦角林治疗，1800–3500元/年（含垂体MRI增强、PRL动态监测）

四、方案快速选择指南

• •预算有限（≤3000元/年）：首选生活方式干预+低剂量激素序贯
• •有生育需求且经济允许（≥3万元）：优先GnRH脉冲泵治疗（妊娠率约65%）
• •闭经超3年伴骨量下降：必须启动骨健康管理+激素替代，避免骨折风险